Cargando…
Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management
Drug-induced thrombotic microangiopathy (DITMA) represents 10%–13% of all thrombotic microangiopathy (TMA) cases and about 20%–30% of secondary TMAs, just behind pregnancy-related and infection-related forms. Although the list of drugs potentially involved as causative for TMA are rapidly increasing...
Autores principales: | Mazzierli, Tommaso, Allegretta, Federica, Maffini, Enrico, Allinovi, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868185/ https://www.ncbi.nlm.nih.gov/pubmed/36699080 http://dx.doi.org/10.3389/fphar.2022.1088031 |
Ejemplares similares
-
An Update in Drug-Induced Thrombotic Microangiopathy
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2020) -
Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018) -
Drug-induced Thrombotic Microangiopathy Caused by Gemcitabine
por: Hasan, Askari, et al.
Publicado: (2018) -
Drug-Induced Thrombotic Microangiopathy Resulting in ESRD
por: Agarwal, Krishna A., et al.
Publicado: (2020) -
Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
por: Allinovi, Marco, et al.
Publicado: (2017)